IMU's "vaccines" seem to be great in every aspect in terms of its result to produce cancer reduction, however its inability to produce these vaccines is the real question at hand, along with the large amount of shares on issue.
Will the manufacturing facility be able to produce and why is there a large amount of shares on issue when compared to stocks like CSL?\
Any Advice is Welcomed.
DYOR
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-89
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
